Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Abroad (travel likely)RecruitingPHASE3

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking Union Medical College Hospital (PUMCH)., Beijing, Beijing Municipality, China
Contact: Study coordinator (Bing Han, PhD) · Hanbing_Li@sina.com.cn · 010-69155027

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Abroad (travel likely)RecruitingPHASE2, PHASE3

Tianjin, China

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

Paroxysmal Nocturnal Hemoglobinuria

Abroad (travel likely)RecruitingPHASE3

Toronto, Canada · Medellín, Colombia

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

Paroxysmal Nocturnal Hemoglobinuria

Abroad (travel likely)RecruitingPHASE3

Ribeirão Preto, Brazil · Santo André, Brazil

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Abroad (travel likely)RecruitingPHASE3

New Brunswick, United States · Philadelphia, United States